We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 27, 2022

Long-Term Efficacy and Safety of Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients With ASCVD

The Lancet


Additional Info

The Lancet
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Lancet 2022 Jul 18;[EPub Ahead of Print], BK Kim, SJ Hong, YJ Lee, SJ Hong, KH Yun, BK Hong, JH Heo, SW Rha, YH Cho, SJ Lee, CM Ahn, JS Kim, YG Ko, D Choi, Y Jang, MK Hong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading